Symbol
| LAMA4
| contributors: mct/npt - updated : 07-01-2014
|
HGNC name
| laminin, alpha 4
|
HGNC id
| 6484
|
corresponding disease(s)
|
CMD1JJ
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
|  
|
splicing variant with hexapeptide insertion in glioma and neuroblastoma | constitutional
| germinal mutation
|  
|  
|  
|
2 novel amino acid residue-altering mutations (2828C>T [Pro943Leu] and 3217C>T [Arg1073X]) in the integrin-interacting domain of the LAMA4 gene and 1 mutation (785C>T [Ala262Val]) in the ILK gene in dilated cardiomyopathy (Knoll 2007) | tumoral
|  
|  
| --over
|  
|
in hepatocellular carcinomas, strongly correlated with tumor invasion, incomplete or no envelope and tumor bolt (Huang 2008) | |
Variant & Polymorphism
|
| |
Candidate gene
| probably a novel supplementary marker for HCC diagnosis |
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
might be a molecular target in the future cancer therapy |
| | |
| mice lacking the presynaptic organizer Lama4 retained most of the synaptic cleft components but exhibited synaptic alterations reminiscent of those observed in aged animals | |
reduced ability of immune cells to penetrate the vessel wall in mice deficient in Lama4 |